• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Herpes Simplex Infections - Pipeline Review, H2 2011 - Product Image

Herpes Simplex Infections - Pipeline Review, H2 2011

  • Published: September 2011
  • 111 pages
  • Global Markets Direct

Herpes Simplex Infections - Pipeline Review, H2 2011

Summary

Global Markets Direct’s, 'Herpes Simplex Infections - Pipeline Review, H2 2011', provides an overview of the Herpes Simplex Infections therapeutic pipeline. This report provides information on the therapeutic development for Herpes Simplex Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Herpes Simplex Infections. 'Herpes Simplex Infections - Pipeline Review, H2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Herpes Simplex Infections.
- A review of the Herpes Simplex Infections products under READ MORE >



List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Herpes Simplex Infections Overview
Therapeutics Development
An Overview of Pipeline Products for Herpes Simplex Infections
Herpes Simplex Infections Therapeutics under Development by Companies
Herpes Simplex Infections Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Herpes Simplex Infections Therapeutics - Products under Development by Companies
Herpes Simplex Infections Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Herpes Simplex Infections Therapeutics Development
Vical Incorporated
Amgen Inc.
Antigenics, Inc.
Pfizer Inc.
CEL-SCI Corporation
Mymetics Corporation
Nutra Pharma Corporation
CytoGenix, Inc.
Alnylam Pharmaceuticals, Inc
Flamel Technologies S.A.
Starpharma Holdings Limited
Summit Corporation plc
BioAlliance Pharma SA
Clavis Pharma ASA
Piramal Life Sciences Limited
Quigley Pharma, Inc.
Osel Inc.
AiCuris GmbH & Co. KG
Okairos
Asahi Kasei Pharma
AlphaVax, Inc.
IC-MedTech, Inc.
Nitric Biotherapeutics, Inc.
Romark Laboratories, L.C.
Lumavita AG
Juvaris BioTherapeutics, Inc.
NanoBio Corporation
PepTcell Limited
Genocea Biosciences, Inc.
Beech Tree Labs, Inc.
EMS S.A.
Herpes Simplex Infections - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Tolecine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BA-021 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RPI-78M - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RPI-MN - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Simplivir - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CEL-1000 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HSV Vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NB-001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ImmunoVEX HSV2 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LMV-601 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HSV-2 Vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HSV Vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CP-4010 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PP9706642 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HerpV - Drug Profile
Product Description
Mechanism of Action
R&D Progress
QR-446 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AIC316 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Prednisolone Phosphate + Acyclovir - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Valtrex + Aspirin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Acyclovir - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Valacyclovir - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Valtrex - Drug Profile
Product Description
Mechanism of Action
R&D Progress
VivaGel - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Zicam - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Genvir - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Valacyclovir - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RNAi Therapeutic - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BTL-TML-HSV - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Human Herpes Virus (HHV) Specific Immune Effector (IE) Cell Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Zovirax - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SPL7013 Gel - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Acyclovir - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Antiviral Program - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MucoCept Program - Drug Profile
Product Description
Mechanism of Action
R&D Progress
pPJV7630 + pPJV2012 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HSV-2 Therapeutic Vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HSV-2 Prophylactic Vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Penciclovir - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AK-120 - Drug Profile
Famciclovir - Drug Profile
JVRS-100 + HSV-2 Vaccine - Drug Profile
New Thiazolides - Drug Profile
Herpes Simplex Type 2 Virus Vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drug For Herpes Simplex - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Herpes Simplex Infections Therapeutics – Drug Profile Updates
Herpes Simplex Infections Therapeutics - Discontinued Products
Herpes Simplex Infections - Featured News
Sep 05, 2011: AiCuris To Present Results Of Resistance Analysis From Phase II Clinical Trial Of AIC316
Jul 18, 2011: AiCuris's AIC316 Shows Efficacy In Phase II Results
Jun 28, 2011: Vical Provides Herpes Simplex Vaccine Updates At BIO International Convention
Jun 27, 2011: Agenus’s Herpes Study Results Presented At BIO International Convention Show Robust Immune Response
May 11, 2011: NanoBio And GSK Commence Phase III Studies Of Nanoemulsion-based OTC Treatment For Cold Sores
Feb 08, 2011: Vical And University Of Washington Receive US Patent For Herpes Simplex Vaccine
Feb 07, 2011: BioAlliance Pharma Presents Results Of International Survey Performed With Nielsen In Patients Suffering From Herpes Labialis
Jan 07, 2011: Chimerix Starts CMX001 Clinical Study For Treatment Of dsDNA Viral Infections
Dec 08, 2010: AiCuris Completes Phase II Genital Herpes Trial With AIC316
Nov 22, 2010: Chimerix's CMX001 Demonstrates To Be Potent Inhibitor Of Herpes Simplex Viruses In Preclinical Study
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Herpes Simplex Infections, H2 2011
Products under Development for Herpes Simplex Infections – Comparative Analysis, H2 2011
Number of Products under Development by Companies, H2 2011
Number of Products under Development by Companies, H2 2011
Number of Products under Investigation by Universities/Institutes, H2 2011
Comparative Analysis by Late Stage Development, H2 2011
Comparative Analysis by Mid Clinical Stage Development, H2 2011
Comparative Analysis by Early Clinical Stage Development, H2 2011
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2011
Products under Development by Companies, H2 2011
Products under Development by Companies, H2 2011
Products under Development by Companies, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Vical Incorporated, H2 2011
Amgen Inc., H2 2011
Antigenics, Inc., H2 2011
Pfizer Inc., H2 2011
CEL-SCI Corporation, H2 2011
Mymetics Corporation, H2 2011
Nutra Pharma Corporation, H2 2011
CytoGenix, Inc., H2 2011
Alnylam Pharmaceuticals, Inc, H2 2011
Flamel Technologies S.A., H2 2011
Starpharma Holdings Limited, H2 2011
Summit Corporation plc, H2 2011
BioAlliance Pharma SA, H2 2011
Clavis Pharma ASA, H2 2011
Piramal Life Sciences Limited, H2 2011
Quigley Pharma, Inc., H2 2011
Osel Inc., H2 2011
AiCuris GmbH & Co. KG, H2 2011
Okairos, H2 2011
Asahi Kasei Pharma, H2 2011
AlphaVax, Inc., H2 2011
IC-MedTech, Inc., H2 2011
Nitric Biotherapeutics, Inc., H2 2011
Romark Laboratories, L.C., H2 2011
Lumavita AG, H2 2011
Juvaris BioTherapeutics, Inc., H2 2011
NanoBio Corporation, H2 2011
PepTcell Limited, H2 2011
Genocea Biosciences, Inc., H2 2011
Beech Tree Labs, Inc., H2 2011
EMS S.A., H2 2011
Assessment by Monotherapy Products, H2 2011
Assessment by Combination Products
Assessment by Stage and Route of Administration, H2 2011
Assessment by Molecule Type, H2 2011
Herpes Simplex Infections Therapeutics – Drug Profile Updates
Discontinued Products

List of Figures
Number of Products under Development for Herpes Simplex Infections, H2 2011
Products under Development for Herpes Simplex Infections – Comparative Analysis, H2 2011
Products under Development by Companies, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Late Stage Products, H2 2011
Mid Clinical Stage Products, H2 2011
Early Clinical Stage Products, H2 2011
Discovery and Pre-Clinical Stage Products, H2 2011
Assessment by Monotherapy Products, H2 2011
Assessment by Combination Products, H2 2011
Assessment by Route of Administration, H2 2011
Assessment by Stage and Route of Administration, H2 2011
Assessment by Molecule Type, H2 2011
Assessment by Stage and Molecule Type, H2 2011

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos